MiMedx Group (NASDAQ:MDXG) Price Target Cut to $8.00 by Analysts at Cantor Fitzgerald

MiMedx Group (NASDAQ:MDXG) had its price target trimmed by Cantor Fitzgerald from $12.00 to $8.00 in a report published on Tuesday,Benzinga reports. The firm currently has an overweight rating on the stock.

Other analysts also recently issued reports about the stock. Lake Street Capital decreased their price objective on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, January 20th. Wall Street Zen upgraded shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Finally, Mizuho cut their price objective on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Wednesday, December 17th. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, MiMedx Group presently has an average rating of “Moderate Buy” and a consensus target price of $9.33.

MiMedx Group Stock Up 0.8%

MDXG opened at $5.16 on Tuesday. The firm has a market cap of $764.20 million, a P/E ratio of 19.11 and a beta of 1.59. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41. The business has a 50 day moving average price of $6.01 and a 200 day moving average price of $6.68. MiMedx Group has a twelve month low of $4.89 and a twelve month high of $8.50.

Hedge Funds Weigh In On MiMedx Group

A number of hedge funds and other institutional investors have recently made changes to their positions in MDXG. CWM LLC boosted its holdings in shares of MiMedx Group by 63.8% in the 2nd quarter. CWM LLC now owns 4,857 shares of the company’s stock worth $30,000 after acquiring an additional 1,892 shares in the last quarter. Kemnay Advisory Services Inc. bought a new position in MiMedx Group in the 4th quarter valued at $48,000. PNC Financial Services Group Inc. boosted its stake in MiMedx Group by 1,808.4% in the second quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock worth $46,000 after purchasing an additional 7,107 shares in the last quarter. State of Alaska Department of Revenue acquired a new position in MiMedx Group in the third quarter worth $54,000. Finally, Jain Global LLC bought a new stake in shares of MiMedx Group during the fourth quarter worth $73,000. 79.15% of the stock is owned by institutional investors.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.